ELTX

Elicio Therapeutics Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↑ 5/10
  • Value↑ 5/10
Elicio Therapeutics sales and earnings growth
ELTX Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 38.78%
  • FCF Y/Y↓ -9.51%
Elicio Therapeutics gross and profit margin trends
ELTX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -296.76%
Elicio Therapeutics net debt vs free cash flow
ELTX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -28.5

Elicio Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks